内容紹介
Determination of the Appropriate Timing of Aprepitant Administration for Nausea in Patients with Head and Neck Cancer Receiving Combination Chemotherapy with Docetaxel, Nedaplatin(Divided Doses for 5 Days), and 5-Fluorouracil
Summary
The objective of this study was to determine the appropriate timing of aprepitant administration in patients with oral cancer by comparing the antiemetic effect of aprepitant administered on the first day(first-day group)and third day(third-day group)of combination chemotherapy with docetaxel, nedaplatin(divided doses for 5 days), and 5-fluorouracil. 1.In both groups, very few cases of vomiting were observed. Therefore, we could not compare the incidence of vomiting. 2.The mean highest grade of nausea in the third-day group was significantly higher than that in the first-day group(2.33±0.71 vs 0.78±0.22, p=0.002; U-test). 3.In addition, the mean area under the curve of the chronological changes in the grade of nausea in the third-day group was significantly higher than that in the first-day group(13.44±9.58 vs 3.11±3.59, p=0.019; U-test). 4.The incidence of nausea of grade 2 or higher in the first-day group was significantly lower than that in the third-day group(11.1%[1/9]vs 88.9%[8/9], p<0.001; χ2 test). These results indicate that initiation of aprepitant administration on the first day of combination chemotherapy with docetaxel, nedaplatin, and 5-fluorouracil successfully prevented the development of nausea in patients with oral cancer.
要旨
口腔癌に対してdocetaxel,nedaplatin(5日間分割投与),5-fluorouracilの3剤併用化学療法を実施した患者を対象に,aprepitantをコース初日から投与した場合とコース3日目から投与した場合の制吐効果を比較し,適切なaprepitantの投与タイミングを明らかにすることを目的とした。1.嘔吐は両群ともほとんどみられず,比較できなかった。2.最大悪心gradeは初日群が平均0.78±0.22であったのに対し,3日目群では平均2.33±0.71と有意(p=0.002,U-test)に高かった。3.経日的な悪心gradeの推移下面積(AUC)も初日群が平均3.11±3.59であったのに対し,3日目群では平均13.44±9.58と有意(p=0.019,U-test)に高かった。4.3日目群ではgrade 2以上の悪心が8/9例(88.9%)にみられたのに対し,初日群では1/9(11.1%)と有意(p<0.001,χ2 test)に低かった。aprepitantは初日から投与することで悪心の発現をよく抑えることが確認された。
目次
Summary
The objective of this study was to determine the appropriate timing of aprepitant administration in patients with oral cancer by comparing the antiemetic effect of aprepitant administered on the first day(first-day group)and third day(third-day group)of combination chemotherapy with docetaxel, nedaplatin(divided doses for 5 days), and 5-fluorouracil. 1.In both groups, very few cases of vomiting were observed. Therefore, we could not compare the incidence of vomiting. 2.The mean highest grade of nausea in the third-day group was significantly higher than that in the first-day group(2.33±0.71 vs 0.78±0.22, p=0.002; U-test). 3.In addition, the mean area under the curve of the chronological changes in the grade of nausea in the third-day group was significantly higher than that in the first-day group(13.44±9.58 vs 3.11±3.59, p=0.019; U-test). 4.The incidence of nausea of grade 2 or higher in the first-day group was significantly lower than that in the third-day group(11.1%[1/9]vs 88.9%[8/9], p<0.001; χ2 test). These results indicate that initiation of aprepitant administration on the first day of combination chemotherapy with docetaxel, nedaplatin, and 5-fluorouracil successfully prevented the development of nausea in patients with oral cancer.
要旨
口腔癌に対してdocetaxel,nedaplatin(5日間分割投与),5-fluorouracilの3剤併用化学療法を実施した患者を対象に,aprepitantをコース初日から投与した場合とコース3日目から投与した場合の制吐効果を比較し,適切なaprepitantの投与タイミングを明らかにすることを目的とした。1.嘔吐は両群ともほとんどみられず,比較できなかった。2.最大悪心gradeは初日群が平均0.78±0.22であったのに対し,3日目群では平均2.33±0.71と有意(p=0.002,U-test)に高かった。3.経日的な悪心gradeの推移下面積(AUC)も初日群が平均3.11±3.59であったのに対し,3日目群では平均13.44±9.58と有意(p=0.019,U-test)に高かった。4.3日目群ではgrade 2以上の悪心が8/9例(88.9%)にみられたのに対し,初日群では1/9(11.1%)と有意(p<0.001,χ2 test)に低かった。aprepitantは初日から投与することで悪心の発現をよく抑えることが確認された。